Benjamin Gibson, PharmD, PAHM

New research highlights abemaciclib and ribociclib as promising treatments for early HR-positive, HER2-negative breast cancer, emphasizing survival benefits and adverse effects.

Combination therapy with tremelimumab and durvalumab significantly improves survival in patients with liver cancer compared with standard sorafenib treatment.

Abemaciclib and ribociclib have various risks and benefits in treating early breast cancer, highlighting the importance of patient-provider communication.

Clinicians should not just focus on one single nucleotide polymorphism (SNP), but rather consider all SNPs because each factor causes unique adverse effects

Although most health care professionals agree that patients do not need prescriptions for chronic diseases during end-of-life care, patients often receive them anyway.

In contrast to the study findings, the prescribing information for cefiderocol lists different common adverse effects.